South Rampart Pharma Takes Lean to a Different Level
Wall Street Journal / May 14, 2025
The New Orleans biotech is currently raising a tiny $8 million Series A to develop its non-opioid painkiller. It keeps costs low by paying employees cash on an hourly basis—but no salaries.
News
Outcome Capital Announces Partnership of ZIEN Medical and Averra Holdings
Outcome Capital served as exclusive strategic and financial advisor to ZIEN
Read MoreResources
Outcome Capital Life Science Market Pulse, May 2025
Outcome Capital Life Science Market Pulse May 2025 Click to view our LifeSciences Pulse Newsletter
DownloadContact Us for More Information
Would you like to learn more about working with Outcome Capital or discuss your specific needs?
© Outcome Capital 2025. Member of Financial Industry Regulatory Authority (FINRA) and the Securities Investment Protection Corporation (SIPC). Check the background of this firm on FINRA’s BrokerCheck.
Outcome Capital and Outcome Life Sciences are affiliates of Outcome Holdings, LLC
Business Continuity Plan | Privacy Policy | Regulation Best Interest
